Neurocrine Biosciences (NBIX) said late Monday its drug INGREZZA, used to treat tardive dyskinesia, a movement disorder, showed a clinically meaningful response in a late-stage trial.
The company said that after 48 weeks of treatment, 94% of patients achieved either symptomatic remission or clinically meaningful improvement in involuntary movements.
A separate analysis found high hepatic risk factors in patients with tardive dyskinesia, the company said, adding that INGREZZA is the only VMAT2 inhibitor approved for use in patients with hepatic impairment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments